Related Experiment Video
Updated: Mar 25, 2026

09:27
Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
Published on: January 5, 2016
18.2K
ɑ-Synuclein strains and the variable pathologies of synucleinopathies
Wouter Peelaerts1, Veerle Baekelandt2
1Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences, KU Leuven, Leuven, Belgium.
Journal of Neurochemistry
|March 1, 2016
Summary
Prions, misfolded proteins, explain inherited diseases. Now, misfolded alpha-synuclein strains may explain Parkinson
Area of Science:
- Neuroscience
- Protein Misfolding Diseases
- Prion Biology
Background:
- Transmissible agents, prions, cause fatal neurological disorders via protein misfolding.
- Prion-based inheritance involves conformational isomers with unique, heritable fingerprints.
- This concept is now explored for amyloid proteins in neurodegenerative diseases.
Purpose of the Study:
- To examine the pathological role of amyloid proteins in neurodegenerative disorders.
- To investigate alpha-synuclein (ɑ-SYN) structural variants as potential disease strains.
- To explain the clinical heterogeneity observed in synucleinopathies like Parkinson's disease.
Main Methods:
- Review of recent scientific literature on prions and synucleinopathies.
- Analysis of studies investigating alpha-synuclein (ɑ-SYN) misfolding and aggregation.
- Comparison of prion-like behavior of ɑ-SYN with disease phenotypes.
Main Results:
- Misfolded ɑ-SYN variants may function as strains, similar to prions.
- These ɑ-SYN strains exhibit distinct biochemical and functional properties.
- Strain-specific properties correlate with specific phenotypic traits in synucleinopathies.
Conclusions:
- ɑ-SYN strains offer a potential explanation for the diverse clinical presentations of Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
- Understanding ɑ-SYN strains opens new therapeutic avenues and biomarker discovery for synucleinopathies.
- This research highlights the critical role of protein strain variations in neurodegeneration.
Related Concept Videos
Amyloid Fibrils
12.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.9K
Amyloid Fibrils
6.9K
6.9K
Neural Regulation
44.7K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.7K
Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Lysosomal Hydrolases
4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K

